NASDAQ:MRVI Maravai LifeSciences (MRVI) Stock Price, News & Analysis → 😱 This phenomenon is smashing regular market gains (From MillPub) (Ad) Free mrvi Stock Alerts $8.42 +0.22 (+2.68%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$8.13▼$8.7450-Day Range$5.11▼$8.7652-Week Range$4.52▼$16.62Volume1.48 million shsAverage Volume2.52 million shsMarket Capitalization$2.12 billionP/E RatioN/ADividend YieldN/APrice Target$11.56 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Maravai LifeSciences alerts: Email Address Maravai LifeSciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.70 Rating ScoreUpside/Downside37.2% Upside$11.56 Price TargetShort InterestBearish5.93% of Float Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews Sentiment0.15Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.15) to ($0.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.72 out of 5 starsMedical Sector234th out of 926 stocksPharmaceutical Preparations Industry96th out of 420 stocks 3.4 Analyst's Opinion Consensus RatingMaravai LifeSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageMaravai LifeSciences has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.93% of the float of Maravai LifeSciences has been sold short.Short Interest Ratio / Days to CoverMaravai LifeSciences has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Maravai LifeSciences has recently increased by 23.83%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMaravai LifeSciences does not currently pay a dividend.Dividend GrowthMaravai LifeSciences does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMaravai LifeSciences has received a 67.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Deoxyribonucleic acid (DNA)", "Microbiology laboratory services for research", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Maravai LifeSciences is -1.23. Previous Next 2.3 News and Social Media Coverage News SentimentMaravai LifeSciences has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Maravai LifeSciences this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for MRVI on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows2 people have added Maravai LifeSciences to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Maravai LifeSciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.22% of the stock of Maravai LifeSciences is held by insiders.Percentage Held by Institutions50.25% of the stock of Maravai LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Maravai LifeSciences are expected to grow in the coming year, from ($0.15) to ($0.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Maravai LifeSciences is -9.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Maravai LifeSciences is -9.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaravai LifeSciences has a P/B Ratio of 2.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad MillPub😱 This phenomenon is smashing regular market gainsThanks to a little-known “Pathfinder” trading phenomenon… Traders have recently unlocked one of the most powerful idea-generation sources in the history of trading. At every single market open.Click here to save your seat and join the next LIVE workshop! About Maravai LifeSciences Stock (NASDAQ:MRVI)Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.Read More MRVI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRVI Stock News HeadlinesMay 1, 2024 | americanbankingnews.comMaravai LifeSciences (MRVI) to Release Quarterly Earnings on WednesdayApril 30, 2024 | markets.businessinsider.comCraig-Hallum Keeps Their Buy Rating on Maravai Lifesciences Holdings (MRVI)May 1, 2024 | MillPub (Ad)😱 This phenomenon is smashing regular market gainsThanks to a little-known “Pathfinder” trading phenomenon… Traders have recently unlocked one of the most powerful idea-generation sources in the history of trading. At every single market open.April 30, 2024 | businesswire.comTriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping TechnologyApril 18, 2024 | businesswire.comTriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance ProductionApril 17, 2024 | msn.comMaravai LifeSciences Holdings (MRVI) Price Target Increased by 6.78% to 9.98April 10, 2024 | globenewswire.comMaravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024March 19, 2024 | finance.yahoo.comShould You Sell Maravai LifeSciences (MRVI)?May 1, 2024 | MillPub (Ad)😱 This phenomenon is smashing regular market gainsThanks to a little-known “Pathfinder” trading phenomenon… Traders have recently unlocked one of the most powerful idea-generation sources in the history of trading. At every single market open.March 12, 2024 | finance.yahoo.comMRVI Apr 2024 2.500 callMarch 12, 2024 | globenewswire.comMaravai LifeSciences Announces March 2024 Investor Conference ScheduleMarch 11, 2024 | finance.yahoo.comMRVI Apr 2024 2.500 putFebruary 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Maravai Lifesciences Amid Strong Financial Performance and Growth OutlookFebruary 24, 2024 | uk.news.yahoo.com300 from RNAS Culdrose join largest NATO exercise since the Cold WarFebruary 24, 2024 | finance.yahoo.comMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Just Released Its Annual Results And Analysts Are Updating Their EstimatesFebruary 23, 2024 | marketwatch.comMaravai LifeSciences Shares Rise 65% After 4Q ResultsFebruary 23, 2024 | markets.businessinsider.comSmall-Cap Maravai LifeSciences' Q4 Outperforms Expectations, Analyst shows Optimism Around 2024 GuidanceFebruary 23, 2024 | finance.yahoo.comMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q4 2023 Earnings Call TranscriptFebruary 23, 2024 | markets.businessinsider.comMaravai Lifesciences Holdings: Poised for Growth with Strong Q4 Performance and Promising FY2024 OutlookFebruary 23, 2024 | fool.comMaravai LifeSciences (MRVI) Q4 2023 Earnings Call TranscriptFebruary 22, 2024 | msn.comMaravai 2024 revenue guidance propels stock 20% higherFebruary 22, 2024 | msn.comMaravai LifeSciences Holdings GAAP EPS of -$0.80 misses by $0.78, revenue of $74.14M beats by $9.8MFebruary 22, 2024 | finance.yahoo.comMaravai LifeSciences Holdings Inc (MRVI) Faces Net Loss in 2023 Despite Revenue OutperformanceFebruary 22, 2024 | globenewswire.comMaravai LifeSciences Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 21, 2024 | finance.yahoo.comTriLink BioTechnologies® Solidifies IP Position with Awarded Patents for CleanCap® Capping Technology in China and CanadaFebruary 17, 2024 | finance.yahoo.comMRVI Jan 2025 5.000 callFebruary 17, 2024 | finance.yahoo.comMRVI Jan 2025 10.000 putSee More Headlines Receive MRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today5/01/2024Next Earnings (Confirmed)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRVI CUSIPN/A CIK1823239 Webwww.maravai.com Phone858-546-0004FaxN/AEmployees650Year FoundedN/APrice Target and Rating Average Stock Price Target$11.56 High Stock Price Target$17.00 Low Stock Price Target$7.00 Potential Upside/Downside+37.2%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-119,030,000.00 Net Margins-41.19% Pretax Margin213.79% Return on Equity-1.31% Return on Assets-0.55% Debt Debt-to-Equity Ratio0.70 Current Ratio8.00 Quick Ratio7.41 Sales & Book Value Annual Sales$288.95 million Price / Sales7.33 Cash Flow$0.10 per share Price / Cash Flow82.89 Book Value$3.14 per share Price / Book2.68Miscellaneous Outstanding Shares251,400,000Free Float250,847,000Market Cap$2.12 billion OptionableOptionable Beta0.01 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Carl W. Hull (Age 65)Co-Founder & Executive Chairman Comp: $617.67kMr. William E. Martin III (Age 49)Chief Executive Officer Comp: $987.86kMr. Kevin M. Herde (Age 52)Executive VP & CFO Comp: $548.62kDr. Peter Michael Leddy Ph.D. (Age 61)Executive VP & Chief Administrative Officer Comp: $583.39kMs. Christine Dolan (Age 56)Executive VP & GM of Cygnus Technologies Comp: $536.63kMr. Andrew Burch (Age 55)President of Nucleic Acid Production Comp: $425.15kMs. Debra HartSenior Director of Investor RelationsMr. Kurt Oreshack (Age 43)Executive VP, General Counsel & Secretary Comp: $701.4kMs. Rebecca BuzzeoExecutive VP & Chief Commercial OfficerDr. Kate E. Broderick Ph.D.Chief Innovation OfficerMore ExecutivesKey CompetitorsDeciphera PharmaceuticalsNASDAQ:DCPHKeros TherapeuticsNASDAQ:KROSAmphastar PharmaceuticalsNASDAQ:AMPHTG TherapeuticsNASDAQ:TGTXGeronNASDAQ:GERNView All CompetitorsInstitutional OwnershipNorden Group LLCBought 33,444 shares on 4/30/2024Ownership: 0.013%Principal Financial Group Inc.Bought 398,306 shares on 4/29/2024Ownership: 0.163%China Universal Asset Management Co. Ltd.Bought 10,142 shares on 4/29/2024Ownership: 0.010%Simplicity Wealth LLCBought 29,613 shares on 4/24/2024Ownership: 0.012%Norden Group LLCBought 33,444 shares on 4/19/2024Ownership: 0.013%View All Institutional Transactions MRVI Stock Analysis - Frequently Asked Questions Should I buy or sell Maravai LifeSciences stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MRVI shares. View MRVI analyst ratings or view top-rated stocks. What is Maravai LifeSciences' stock price target for 2024? 10 brokers have issued 1 year target prices for Maravai LifeSciences' shares. Their MRVI share price targets range from $7.00 to $17.00. On average, they predict the company's stock price to reach $11.56 in the next twelve months. This suggests a possible upside of 37.2% from the stock's current price. View analysts price targets for MRVI or view top-rated stocks among Wall Street analysts. How have MRVI shares performed in 2024? Maravai LifeSciences' stock was trading at $6.55 on January 1st, 2024. Since then, MRVI stock has increased by 28.5% and is now trading at $8.42. View the best growth stocks for 2024 here. Are investors shorting Maravai LifeSciences? Maravai LifeSciences saw a increase in short interest in April. As of April 15th, there was short interest totaling 6,340,000 shares, an increase of 23.8% from the March 31st total of 5,120,000 shares. Based on an average daily volume of 2,740,000 shares, the short-interest ratio is currently 2.3 days. Currently, 5.9% of the shares of the company are sold short. View Maravai LifeSciences' Short Interest. When is Maravai LifeSciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our MRVI earnings forecast. How can I listen to Maravai LifeSciences' earnings call? Maravai LifeSciences will be holding an earnings conference call on Wednesday, May 8th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link. How were Maravai LifeSciences' earnings last quarter? Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) announced its earnings results on Thursday, February, 22nd. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.01. The business had revenue of $74.14 million for the quarter, compared to analyst estimates of $62.99 million. Maravai LifeSciences had a negative net margin of 41.19% and a negative trailing twelve-month return on equity of 1.31%. What ETF holds Maravai LifeSciences' stock? Morningstar US Small Growth holds 10,940 shares of MRVI stock, representing 4.94% of its portfolio. What guidance has Maravai LifeSciences issued on next quarter's earnings? Maravai LifeSciences issued an update on its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $265.0 million-$285.0 million, compared to the consensus revenue estimate of $261.0 million. When did Maravai LifeSciences IPO? Maravai LifeSciences (MRVI) raised $1.3 billion in an IPO on Friday, November 20th 2020. The company issued 50,000,000 shares at $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs acted as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers. Who are Maravai LifeSciences' major shareholders? Maravai LifeSciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Principal Financial Group Inc. (0.16%), Wedmont Private Capital (0.02%), Norden Group LLC (0.01%), Norden Group LLC (0.01%), Simplicity Wealth LLC (0.01%) and China Universal Asset Management Co. Ltd. (0.01%). How do I buy shares of Maravai LifeSciences? Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MRVI) was last updated on 5/1/2024 by MarketBeat.com Staff From Our Partners😱 This phenomenon is smashing regular market gainsMillPubBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldYour bank is lying to you.MyBankTrackerDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing4 coins to be the “Next Bitcoin”True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
